ArticlePatient preference and adherence2014
Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study.
Article in Patient preference and adherence, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.Blood advances · 2021Guideline
- Patient values and preferences regarding VTE disease: a systematic review to inform American Society of Hematology guidelines.Blood advances · 2020Pooled it
- Trial
- Article
- Quality of life in oncological patients with venous thromboembolic disease.Research and practice in thrombosis and haemostasis · 2024Review
- Measurement of adherence and health-related quality of life during anticoagulation therapy in cancer-associated venous thromboembolism (VTE): a multicenter quantitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2022Article
- Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Review
- Anticoagulant use and associated outcomes in older patients receiving home palliative care: a retrospective cohort study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022Article
- Anticoagulation for atrial fibrillation in active cancer.Oncology letters · 2022Review
- Cancer-associated venous thromboembolism.Nature reviews. Disease primers · 2022Review
- Cancer patients' experiences of the diagnosis and treatment of incidental pulmonary embolism (a qualitative study).PloS one · 2022Observational
- New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism.Drug design, development and therapy · 2022Review
- The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines.Thrombosis journal · 2021Article
- A mixed-methods study to evaluate a patient-designed tool to reduce harm from cancer-associated thrombosis: The EMPOWER study.Research and practice in thrombosis and haemostasis · 2021Article
- Management of Cancer-Associated Venous Thrombosis: A Nationwide Survey among Danish Oncologists.TH open : companion journal to thrombosis and haemostasis · 2021Article
- Updates in Anticoagulation Therapy Monitoring.Biomedicines · 2021Review
- Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban.Research and practice in thrombosis and haemostasis · 2020Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism is a common complication of cancer and its treatments. Treatment of cancer-associated thrombosis (CAT) differs from treatment of thrombosis in noncancer patients, requiring a daily injection of low-molecular-weight heparin (LMWH) for 6 months instead of an oral anticoagulant. Previous research suggested LMWH is an acceptable intervention in the treatment of CAT, yet clinical practice and therapeutic opportunities have changed in the decade since the study was conducted. Furthermore, in the previous study there was acknowledged selection bias in participant recruitment. There is increasing clinical use of the novel oral anticoagulants, although their efficacy and safety is yet to be demonstrated within the cancer population. The experience of patients receiving anticoagulation for CAT will inform future practice with respect to quality of life and adherence to anticoagulation therapy.
aimTo explore the acceptability of long-term LMWH for the treatment of CAT in the contexts of living with cancer and quality of life.
designQualitative study of cancer patients who had been receiving LMWH for at least 3 months for CAT was undertaken. Audiotaped semistructured interviews were conducted and transcribed. Thematic analysis was undertaken until theoretical saturation. SETTING/
participantsFourteen patients attending a palliative care or CAT clinic were interviewed. Participants had been receiving LMWH for a median 6 months.
resultsParticipants reported distressing symptoms associated with symptomatic CAT, which they rated as worse than their cancer experiences. LMWH was considered an acceptable intervention despite challenges of long-term injections. Several adaptive techniques were reported to optimize ongoing injections. Participants would only favor a novel oral anticoagulant if it was equivalent to LMWH in efficacy and safety.
conclusionAlthough LMWH remains an acceptable intervention for the treatment of CAT, its long-term use is associated with bruising and deterioration of injection sites. These are considered an acceptable trade-off against their strongly negative experiences of symptomatic venous thromboembolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.